Next Article in Journal
Stem Cell-Like Properties of CK2β-down Regulated Mammary Cells
Previous Article in Journal
Most Do, but Some Do Not: CD4+CD25 T Cells, but Not CD4+CD25+ Treg Cells, Are Cytolytic When Redirected by a Chimeric Antigen Receptor (CAR)
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessReview
Cancers 2017, 9(9), 113; doi:10.3390/cancers9090113

Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck

Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
*
Author to whom correspondence should be addressed.
Academic Editor: David Wong
Received: 21 August 2017 / Revised: 30 August 2017 / Accepted: 30 August 2017 / Published: 31 August 2017
View Full-Text   |   Download PDF [289 KB, uploaded 31 August 2017]

Abstract

Cancers of the head and neck region are among the leading causes of cancer-related mortalities worldwide. Oral leukoplakia and erythroplakia are identified as precursor lesions to malignancy. Patients cured of an initial primary head and neck cancer are also susceptible to developing second primary tumors due to cancerization of their mucosal field. Multi-step acquisition of genetic mutations leading to tumorigenesis and development of invasive cancer has been previously described. Recently, whole exome sequencing of tumor specimens has helped to identify driver mutations in this disease. For these reasons, chemoprevention or the use of systemic or biologic agents to prevent carcinogenesis is an attractive concept in head and neck cancers. Nonetheless, despite extensive clinical research in this field over the past couple decades, no standard of care option has emerged. This review article reports on targeted interventions that have been attempted in clinical trials to date, and focuses on novel molecular pathways and drugs in development that are worthy of being tested for this indication as part of future endeavors. View Full-Text
Keywords: head and neck cancer; oral cancer; clinical trial; second primary tumor; chemoprevention; retinoids head and neck cancer; oral cancer; clinical trial; second primary tumor; chemoprevention; retinoids
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Bhatia, A.; Burtness, B. Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck. Cancers 2017, 9, 113.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top